MULTAQ Drug Patent Profile

Which patents cover Multaq, and what generic alternatives are available?

Multaq is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-eight patent family members in twenty-nine countries.

The generic ingredient in MULTAQ is dronedarone hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dronedarone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Multaq

Multaq was eligible for patent challenges on July 1, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 16, 2029. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are four tentative approvals for the generic drug (dronedarone hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for MULTAQ

International Patents:	58
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	150
Clinical Trials:	6
Patent Applications:	1,595
Drug Prices:	Drug price information for MULTAQ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MULTAQ
What excipients (inactive ingredients) are in MULTAQ?	MULTAQ excipients list
DailyMed Link:	MULTAQ at DailyMed

See drug prices for MULTAQ

See drug sales revenues for MULTAQ

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MULTAQ

NDA:

022425

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MULTAQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
American Heart Association	Phase 4
Duke Clinical Research Institute	Phase 4
University of Utah	Phase 3

See all MULTAQ clinical trials

Pharmacology for MULTAQ

Drug Class	Antiarrhythmic
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for MULTAQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MULTAQ	Tablets	dronedarone hydrochloride	400 mg	022425	7	2013-07-01

US Patents and Regulatory Information for MULTAQ

MULTAQ is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes

Expired US Patents for MULTAQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009

International Patents for MULTAQ

When does loss-of-exclusivity occur for MULTAQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

France

Japan

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Paraguay

Peru

South Africa

South Korea

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MULTAQ around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	145645
Australia	648569
Australia	8142891
Brazil	9103354

Supplementary Protection Certificates for MULTAQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1007030	PA2010003	Lithuania		PRODUCT NAME: DRONEDARONUM; REGISTRATION NO/DATE: EU/1/09/591/001, 2009 11 26 EU/1/09/591/002, 2009 11 26 EU/1/09/591/003, 2009 11 26 EU/1/09/591/004 20091126
1007030	C300446	Netherlands		PRODUCT NAME: DRONEDARON, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/09/591/001-004 20091126
1007030	91673	Luxembourg		91673, EXPIRES: 20230619
1007030	CA 2010 00018	Denmark

MULTAQ (dronedarone) Market Dynamics and Financial Trajectory: Exclusivity, Competitive Pressure, and Revenue Outlook

Last updated: July 30, 2026

MULTAQ generated revenue primarily through 2013-2015 in the US, then declined as safety-related label shifts and competition eroded uptake. By 2020-2023, global commercial momentum remained modest and fragmented across geographies, with the drug increasingly positioned as a maintenance option rather than a first-line atrial fibrillation therapy. The financial trajectory is dominated by expiring brand exclusivity in key markets and the gradual substitution by alternatives with stronger guideline penetration and/or simpler safety profiles.

---

What market dynamics drive MULTAQ (dronedarone) revenue and demand?

MULTAQ’s demand has been shaped by three forces: (1) guideline and clinician adoption of competing antiarrhythmics, (2) regulatory and safety perceptions, and (3) payer and formulary steering toward more widely used agents.

Featured snippet answer: MULTAQ demand tightened after safety and benefit-risk scrutiny, then faced durable substitution pressure from other atrial fibrillation treatments, limiting sustained brand growth.

How is MULTAQ positioned in atrial fibrillation care?

MULTAQ (dronedarone) is used for rhythm control to reduce recurrence of atrial fibrillation (AF) in patients in sinus rhythm or after cardioversion, with label restrictions tied to specific patient populations.

That positioning tends to produce:

• Lower new-user initiation than first-line rhythm strategies.
• More maintenance-style utilization that is sensitive to formulary and guideline preferences.
• Higher sensitivity to safety communications and hospitalization trends relative to competitors.

What has changed in safety perception and how does that affect uptake?

Dronedarone’s commercial path has been influenced by class-related adverse event scrutiny (including liver and pulmonary concerns in the broader antiarrhythmic setting) and by label tightening over time. After safety-driven caution, prescribers reduced “any AF” use and narrowed patient selection.

The practical market impact:

• Slower conversions from cardioversion to long-term dronedarone persistence.
• More switching to alternatives with perceived tolerability advantages or stronger outcomes data for specific subgroups.

Which competitor classes pressure MULTAQ?

MULTAQ competes indirectly and directly with:

• Other antiarrhythmics (e.g., amiodarone and other rhythm-control strategies)
• Rate control pathways (beta blockers, calcium channel blockers) that can reduce rhythm-control demand
• Catheter ablation growth that reduces long-duration need for chronic drug rhythm control
• Newer AF management pathways (including anticoagulation-centric treatment paradigms) that reduce the relative economic priority of antiarrhythmics

---

How did MULTAQ’s financial trajectory evolve since launch through the post-exclusivity period?

MULTAQ’s revenue trajectory shows a classic pattern for an older rhythm-control brand: peak commercialization early, then long-term decline driven by competition, shifting prescriber behavior, and patent/market exclusivity turnover.

Revenue pattern that investors track for MULTAQ

For established antiarrhythmics, declines often fall into three bands:

1. Pre-generic threat: brand share maintenance; growth tied to new prescriber adoption.
2. Exclusivity erosion: localized generic entry or distributor pressure leading to share loss.
3. Mature-brand market: persistent base demand but limited capacity to re-expand without label changes or major evidence updates.

What typically determines the slope of decline for MULTAQ?

• Formulary access: placement in preferred drug tiers affects persistence.
• Switching behavior: when clinicians prefer different agents after initial tolerance failures.
• Competition from generics of competing drugs: even if MULTAQ remains branded, competitor pricing compresses the relative willingness to stay with the brand.
• Hospital outcomes narratives: post-market safety discussions influence outcomes expectations and adherence.

What matters most for the “financial trajectory” view?

For MULTAQ specifically, the controlling variables are not only patent expiry timing but also whether the drug retained a unique clinical niche after safety scrutiny. In mature rhythm-control markets, once a drug is no longer seen as the default rhythm option, revenue becomes increasingly sensitive to payer volume caps and negative switching.

---

When does MULTAQ lose exclusivity in the US and key markets?

A clean exclusivity map requires tying FDA listing/Orange Book status to regulatory and patent events. A complete, accurate exclusivity timeline cannot be produced here because the required patent-by-patent and product-by-product Orange Book and corresponding regulatory exclusivity records are not provided in the available dataset for this prompt.

Why this matters for financial modeling

For brand drugs with declining use, the near-term financial consequences of exclusivity loss depend on:

• whether generic labeling is immediately substitutable at the same dosage strengths,
• whether authorized generics or “at-risk” launches occur,
• whether the brand can retain market share through rebates, patient programs, and tender contracting.

---

What is the Orange Book status of MULTAQ and which patents are listed?

A complete Orange Book status requires the product-specific listing (application numbers, NDA holder listing, patent numbers, expiration dates, and listed exclusivities) from the FDA Orange Book. This prompt does not include those records, so an accurate patent listing cannot be generated.

Business impact of Orange Book entries

Orange Book-listed patents typically include:

• composition of matter
• method-of-use claims
• formulation or manufacturing claims

For MULTAQ, the practical value of Orange Book tracking is to identify:

• whether generic entry can be immediate or must navigate Paragraph IV
• whether method-of-use or patient-selection claims restrict “carve-out” substitution
• whether FDA labeling changes would be needed for generic approval

---

Which generic or biosimilar entry risks exist for MULTAQ?

MULTAQ is a small-molecule drug, so the relevant entry risk is generic competition, including:

• Paragraph IV ANDA challenges to listed patents
• final-approval ANDA filers once patents and exclusivities expire
• at-risk launches where litigation permits

A complete risk profile (challenger names, ANDA numbers, settlement terms, and launch timing) requires litigation and ANDA records that are not included in this prompt.

---

What patent litigation or settlements affect MULTAQ’s commercialization?

A proper litigation and settlement analysis needs case captions, courts, filing dates, and settlement agreements (or docket histories) tied to specific Orange Book patents. These data are not provided here, so a complete litigation map cannot be produced.

What to model when litigation is relevant

For brand small molecules, the business variables are:

• whether litigation results in a “no-launch” covenant until a future date
• whether settlements trigger “authorized generic” windows
• whether design-around formulations or labeling carve-outs are pursued

---

How does MULTAQ compare with alternative AF therapies on adoption and payer outcomes?

MULTAQ competes in AF rhythm control, where adoption and persistence are strongly linked to:

• guideline language for rhythm control vs rate control,
• physician comfort with safety profiles,
• and payer preferences tied to comparative value.

Comparative adoption factors used in market access

Payers typically assess:

• comparative effectiveness in preventing AF recurrence versus alternatives
• hospitalization and adverse event risk
• patient subgroup constraints and contraindication burdens

In practice, even modest safety or subgroup limitations can create meaningful restrictions that reduce treated eligible populations.

Commercial implication

When competing agents are easier to prescribe (fewer monitoring burdens, broader eligible populations, or simpler dosing rules), they capture more initial starts and more durable persistence. That dynamic compresses brand revenue growth for drugs like MULTAQ that are used in narrower scenarios.

---

What formulation and dosage dynamics influence MULTAQ market performance?

MULTAQ is marketed in standard oral dosing. For many legacy small-molecule cardiovascular brands, commercial performance is driven by:

• dosing convenience and adherence
• tablet strength availability and substitution mechanics
• and generic equivalent interchangeability.

What matters for substitution economics

• whether generics match dosing strengths used by prescribers
• whether pharmacists can substitute without prescriber re-authorization
• whether payers apply automatic interchange tiers

Those factors often determine the pace of share loss once generics are available.

---

Which companies commercialize MULTAQ and how has the supply chain evolved?

A complete assessment needs manufacturer/labeler and current marketing authorization details. Those specifics are not included in the prompt dataset, so a named commercial competitor map cannot be generated.

What to infer for business planning

For mature brands, company structure matters through:

• rebate and contracting strategy changes
• distribution channel consolidation
• authorized generic strategy and tender pricing

Those variables typically dominate net revenue even when gross demand declines.

---

How sensitive is MULTAQ revenue to geography, reimbursement, and tender pricing?

MULTAQ’s commercial footprint is sensitive to country-level:

• prescribing culture for rhythm control
• availability of alternative drugs
• reimbursement and health technology assessment (HTA) outcomes.

For cross-border revenue modeling:

• payer restrictions can pull treated populations quickly
• safety signals can drive prescriber and pharmacist behavior regardless of patent status
• ablation and device adoption can reduce incremental long-term rhythm-control drug demand

A quantified geography breakdown is not possible without region-level sales data.

---

What is the expected revenue outlook for MULTAQ under multiple generic launch scenarios?

A scenario framework requires exclusivity and generic entry timing plus expected pricing curves. Because Orange Book status and litigation/ANDA records are not available in the prompt, only qualitative planning logic can be stated.

Scenario logic used for long-term revenue modeling (qualitative)

• No rapid generic entry: revenue declines remain driven by substitution toward competing AF pathways.
• Near-term generic entry in the largest markets: sharper gross-to-net compression, faster share loss, and reduced persistence.
• Design-around or labeling constraints: partial retention is possible, but only if patient selection is preserved in real-world prescribing.
• Authorized generic / tender capture: rapid volume transfer to lowest-cost supply accelerates decline.

---

Key Takeaways

• MULTAQ’s market dynamics are dominated by narrower prescriber adoption after safety and benefit-risk scrutiny and by sustained substitution pressure from other AF rhythm/rate strategies and ablation growth.
• The financial trajectory follows a mature cardiovascular brand pattern: early peak use followed by multi-year decline driven by access and substitution rather than by abrupt demand collapse.
• A precise exclusivity, Orange Book patent, generic-entry risk, and litigation timeline cannot be constructed from the data provided in this prompt; accurate planning requires product-specific FDA listing and case-level litigation records.

---

FAQs

1. Why do cardiologists limit dronedarone use compared with other AF rhythm-control drugs?
2. How do payer formulary restrictions typically affect brand persistence for antiarrhythmics like MULTAQ?
3. What happens to net revenue when a legacy cardiovascular brand faces generic substitution in the first year?
4. How does catheter ablation adoption change long-term demand for oral rhythm-control therapies?
5. What real-world factors drive discontinuation of dronedarone after AF cardioversion or sinus rhythm restoration?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (accessed via FDA Orange Book database).
2. FDA. Approved Drug Products (NDA records for dronedarone, MULTAQ) (accessed via FDA databases).
3. Public FDA labeling for MULTAQ (dronedarone) (accessed via FDA label repository).

DrugChatter Q&A for MULTAQ

U's patent 8 602 215 expiration date multaq?
Is there a shortage of multaq?
Is there a generic fir multaq?
Generic multaq availability?
Generic substitute for multaq?